NEW YORK,
July 31, 2014 /PRNewswire/ -
Canaccord Genuity is pleased to announce that Marko Kozul, M.D. has agreed to join its Equity
Research team as a Managing Director covering biotechnology
companies.
"The addition of Dr. Marko Kozul
complements our existing global coverage of the Healthcare sector
and affirms our commitment to providing clients with high quality,
independent equity research coverage in dynamic growth sectors,"
stated Dan Daviau, President of
Canaccord Genuity Inc. (US). "In addition to an established track
record in equity research, Marko brings deep clinical and advisory
experience to his role, which gives him an advanced understanding
of the industry drivers impacting his coverage universe."
Based in the firm's San
Francisco office, Dr. Kozul will focus on companies with
advanced biotechnology platforms in the areas of neurology,
immunology, obesity, oncology, and orphan infectious diseases. He
joins senior Healthcare analysts John
Newman and Corey Davis,
building upon the firm's existing US life science practice.
Dr. Kozul joins Canaccord Genuity from Leerink Partners
where he served as a senior biotechnology analyst and was
previously analyst at ThinkEquity Partners and Jefferies &
Company. Earlier in his career, he worked as the Research Director
for Variant Medical Consulting Group and as a consultant for the
Medical & Referral Source Inc. Dr. Kozul earned a Bachelor of
Science in Cellular & Molecular Biology from the University of Michigan and an M.D. from the School
of Medicine at International University
of the Health Sciences. He is a member in good standing of the
American Medical Association, the American Society of Clinical
Oncology and the American Association for Cancer Research, the
American Society of Hematology and the American Academy of
Ophthalmology.
Canaccord Genuity's global equity research team now includes
nine senior healthcare analysts across three continents, covering
Biotechnology, Specialty Pharmaceuticals, Medical Devices, Medical
Diagnostics, Life Sciences Tools and Healthcare Services. At
present, Canaccord Genuity has nearly 150 equity research
professionals globally and more than 950 companies under
coverage.
ABOUT CANACCORD GENUITY:
Canaccord Genuity is the global capital markets division of
Canaccord Genuity Group Inc. (TSX: CF, LSE: CF.), offering
institutional and corporate clients idea-driven investment banking,
merger and acquisition, research, sales and trading services from
offices in 10 countries worldwide. Our team of nearly 1,000 capital
markets and advisory professionals has industry and transactional
expertise in 18 key sectors of the global economy. We are committed
to providing valued services to our clients throughout the entire
lifecycle of their business and operating as a gold standard
independent investment bank - expansive in resources and reach, but
targeted in industry expertise, market focus and individual client
attention.
More information is available at www.canaccordgenuity.com.
ABOUT CANACCORD GENUITY GROUP INC.:
Through its principal subsidiaries, Canaccord Genuity Group Inc.
(the "Company") is a leading independent, full-service financial
services firm, with operations in two principal segments of the
securities industry: wealth management and capital markets. Since
its establishment in 1950, the Company has been driven by an
unwavering commitment to building lasting client relationships. We
achieve this by generating value for our individual, institutional
and corporate clients through comprehensive investment solutions,
brokerage services and investment banking services. The Company has
offices in 10 countries worldwide, including Wealth Management
offices located in Canada,
Australia, the UK and Europe. Canaccord Genuity, the international
capital markets division, operates in Canada, the US, the UK, France, Germany, Ireland, Hong Kong,
China, Singapore,
Australia and Barbados. To us there are no foreign
markets.™
Canaccord Genuity Group Inc. is publicly traded under the symbol
CF on the TSX and the symbol CF. on the London Stock Exchange.
SOURCE Canaccord Genuity Inc.